Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).

CONCLUSION:  BETi merit clinical evaluation as inhibitors of AR splicing and function, with trials demonstrating their blockade in proof of mechanism pharmacodynamic studies.
PMID: 29555663 [PubMed - as supplied by publisher]

Source: Clinical Genitourinary Cancer - March 19, 2018 Category: Cancer & Oncology Authors: Welti J, Sharp A, Yuan W, Dolling DI, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate S, Carreira S, Boysen G, Chinnaiyan A Tags: Clin Cancer Res Source Type: research